IRON
Disc Medicine, Inc.
NASDAQ · Healthcare · Biotechnology · US
$79.23
−0.18%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 189.4M | 170.6M | 96.7M | 69.3M | 33.4M |
| SG&A Expense | 79.9M | 65.4M | 33.0M | 21.9M | 14.0M |
| General & Admin Expense | 79.9M | 65.4M | 33.0M | 21.9M | 14.0M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 269.3M | 236.0M | 129.7M | 91.1M | 47.5M |
| Cost and Expenses | 269.3M | 236.0M | 129.7M | 91.1M | 47.5M |
| Operating Income (EBIT) | (269.3M) | (236.0M) | (129.7M) | (91.1M) | (47.5M) |
| Non-Operating | |||||
| Interest Income | 27.2M | 27.8M | 21.3M | 14.8M | 709.0K |
| Interest Expense | 3.6M | 3.6M | 572.0K | — | — |
| Net Interest Income | 23.7M | 24.2M | 20.7M | 14.8M | 709.0K |
| Other Non-Op Income/Expense | 23.7M | 24.2M | 20.7M | 14.8M | 648.0K |
| Non-Operating Income (excl Interest) | (27.2M) | (27.8M) | (21.3M) | (14.8M) | (648.0K) |
| EBT (Pre-Tax Income) | (245.6M) | (211.8M) | (109.0M) | (76.3M) | (46.8M) |
| Income Tax Expense | 310.0K | 361.0K | 355.0K | 99.0K | — |
| Bottom Line | |||||
| Net Income | (245.9M) | (212.2M) | (109.4M) | (76.4M) | (46.8M) |
| Earnings from Cont. Ops | (245.9M) | (212.2M) | (109.4M) | (76.4M) | (46.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (245.9M) | (212.2M) | (109.4M) | (76.4M) | (46.8M) |
| Per Share | |||||
| Basic EPS | ($6.60) | ($6.01) | ($3.96) | ($3.42) | ($45.05) |
| Diluted EPS | ($6.60) | ($6.01) | ($3.96) | ($3.42) | ($45.05) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 38.7M | 35.3M | 27.6M | 22.3M | 1.0M |
| Diluted Shares Outstanding | 38.7M | 35.3M | 27.6M | 22.3M | 1.0M |
| Profitability Metrics | |||||
| EBITDA | (241.7M) | (207.9M) | (108.3M) | (76.2M) | (46.7M) |
| D&A | 355.0K | 281.0K | 156.0K | 100.0K | 89.0K |
| EBIT | (242.0M) | (208.2M) | (108.4M) | (76.3M) | (46.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026